Adverse Event reporting information can be found in footer

Request a Meeting

PENTASA®’s unique ethyl cellulose coated microgranules release mesalazine independent of intestinal pH1,8-16 and food co-administration3-5

PRODUCT INFORMATION

Pentasa is indicated for the induction and maintenance of remission in mild to moderate Ulcerative Colitis.

PENTASA® (500mg tablets, 1g, 2g and 4g sachets) is licensed in children 6 years of age and older, and given in divided doses.

Adding to its uniqueness, PENTASA once-daily sachets can now be added to yoghurt; providing your mild to moderate UC patients with a simple dosing regimen that can fit easily into their daily routine.3-5

 

Additionally PENTASA OD oral dosing:
  • Achieves symptom remission faster than BD PENTASA dosing and maintains remission for 12 months*17-18
  • Is effective throughout the entire colon, including left sided disease*17-19
  • Achieves significantly better mucosal healing than BD PENTASA dosing in 8 weeks and is maintained over 12 months*17-18

*Included once-daily PENTASA enema for the first 4 weeks

  • Pentasa Slow Release Tablets 500 mg. SmPC.
  • Pentasa Slow Release Tablets 1 g. SmPC.
  • Pentasa Sachet 1 g. SmPC.
  • Pentasa Sachet 2 g. SmPC.
  • Pentasa Sachet 4 g. SmPC.
  • Pentasa Enema 1 g. SmPC.
  • Pentasa Suppositories 1 g. SmPC.
  • Octasa 400 mg MR Tablets. SmPC.
  • Salofalk 500 mg Gastro-resistant Prolonged Release Granules. SmPC.
  • Asacol 400 mg MR Tablets. SmPC.
  • Mezavant XL 1200 mg Gastro-resistant Prolonged Release Tablets. SmPC.
  • Sulfalazine 250 mg/5 ml Oral Suspension. SmPC.
  • Salazopyrin En-Tabs. SmPC.
  • Salazopyrin Tablets. SmPC.
  • Colazide 750 mg Capsules. SmPC.
  • Olsalazine Sodium 250 mg Capsules. SmPC.
  • Flourie B, et al. Aliment Pharmacol Ther. 2013;37(8):767–75.
  • Dignass AU, et al. Clin. Gastroenterol Hepatol. 2009;7(7):762–9.
  • Bokemeyer B, et al. J Crohn’s Colitis. 2012;6:476-82.
  • Probert C.S.J, et al. J Crohn’s Colitis. 2014;8:200–7.
  • Marteau P, et al. Gut. 2005;54(7):960–5.
How Pentasa Works
Impact of Non-Adherence
Pentasa in Paediatrics
Pentasa in Adults
Resources

Job Code: UK-PA-2300006 - Date of preparation: November 2023

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.